Biogen touts new evidence from the gene therapy company it wagered $800M on
A year ago, Biogen made a big bet on a small gene therapy company. Now they have new evidence one of their therapies could work.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters